Medline ® Abstract for Reference 99
of 'Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease'
99
TI
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.
AU
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G
SO
Gastroenterology. 1997;112(2):463.
BACKGROUND& AIMS:
Few data are available concerning the long-term prognosis of chronic liver disease associated with hepatitis C virus infection. This study examined the morbidity and survival of patients with compensated cirrhosis type C.
METHODS:
A cohort of 384 European cirrhotic patients was enrolled at seven tertiary referral hospitals and followed up for a mean period of 5 years. Inclusion criteria were biopsy-proven cirrhosis, abnormal serum aminotransferase levels, absence of complications of cirrhosis, and exclusion of hepatitis A and B viruses and of metabolic, toxic, or autoimmune liver diseases.
RESULTS:
Antibodies against hepatitis C virus were positive in 98% of 361 patients tested. The 5-year risk of hepatocellular carcinoma was 7% and that of decompensation was 18%. Death occurred in 51 patients (13%), with 70% dying of liver disease. Survival probability was 91% and 79% at 5 and 10 years, respectively. Two hundred five patients (53%) were treated with interferon alfa. After adjustment for clinical and serological differences at baseline between patients treated or not treated with interferon, the 5-year estimated survival probability was 96% and 95% for treated and untreated patients, respectively.
CONCLUSIONS:
In this cohort of patients, life expectancy is relatively long, in agreement with the morbidity data showing a slowly progressive disease.
AD
Istituto di Semeiotica e Nefrologia Medica, University of Verona, Italy.
PMID